Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares

Key Points

• CEO Eric Venker sold 200,000 Roivant Sciences shares at an average price of $35.77, generating $7.15 million and reducing his direct stake by 11.12% to 1.6 million shares. This follows two similar 200,000-share sales in June and July.
• ROIV shares fell 0.3% to $34.52, while the company reported a quarterly loss of $0.26 per share, beating estimates, but revenue of $1.44 million came in below forecasts.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and a $35.14 average price target; institutional investors own approximately 64.76% of the stock.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the company's stock in a transaction on Friday, August 28th. The shares were sold at an average price of $35.77, for a total value of $7,154,000.00. Following the transaction, the chief executive officer directly owned 1,599,154 shares in the company, valued at $57,201,738.58. This trade represents a 11.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, July 27th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.95, for a total transaction of $6,990,000.00.
• On Wednesday, June 24th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00.

Roivant Sciences Stock Down 0.3%

ROIV stock traded down $0.12 during midday trading on Tuesday, reaching $34.52. The company's stock had a trading volume of 6,905,942 shares, compared to its average volume of 7,667,241. The business's 50-day simple moving average is $35.27 and its 200-day simple moving average is $31.04. Roivant Sciences Ltd. has a 52 week low of $11.94 and a 52 week high of $37.97. The stock has a market cap of $24.93 billion, a PE ratio of -65.13 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The business had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. As a group, equities analysts forecast that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ROIV shares. Piper Sandler reissued an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, May 21st. HC Wainwright reissued a "buy" rating and issued a $41.00 target price on shares of Roivant Sciences in a research note on Friday. TD Cowen reaffirmed a "buy" rating on shares of Roivant Sciences in a research report on Thursday, August 6th. Bank of America reiterated a "neutral" rating on shares of Roivant Sciences in a research report on Friday, July 31st. Finally, Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $35.14.

Hedge Funds Weigh In On Roivant Sciences

A number of large investors have recently bought and sold shares of ROIV. California State Teachers Retirement System grew its position in Roivant Sciences by 4,212.2% in the second quarter. California State Teachers Retirement System now owns 19,001,068 shares of the company's stock valued at $672,448,000 after purchasing an additional 18,560,434 shares in the last quarter. Morgan Stanley lifted its position in Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company's stock worth $1,266,402,000 after buying an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Roivant Sciences by 365.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company's stock worth $238,323,000 after buying an additional 8,621,567 shares during the last quarter. Norges Bank acquired a new position in shares of Roivant Sciences during the 4th quarter worth about $112,750,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of Roivant Sciences in the 4th quarter valued at about $76,272,000. Institutional investors and hedge funds own 64.76% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source